A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (NCT05330429)
GS-US-587-6156
This trial is No longer recruiting
Registration number NCT05330429
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Sanjeev Gill
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR